Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for ARV-806 in KRAS G12D-mutated Cancer. The expected timing is based on the latest available company guidance and may change.
10/24/25– Presented robust preclinical data at AACR-NCI-EORTC’25. 11/05/25:- Initiated Ph1 KRAS G12D solid tumor trial; initial clinical data expected 2026. 02/24/26:- Ph1 KRAS G12D trial completed once-weekly dose escalation; enrollment ongoing; initial clinical data still expected 2026. 05/12/26:- Phase 1 dose escalation completed; start dose expansion; initial KRAS G12D data still expected 2026. 08/04/26:- Ph1 enrollment complete; initial monotherapy data still expected H2 2026; out-license planned.
Verification
Confirm timing and program details against the company announcement or filing.